Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 1
2006 2
2007 1
2009 1
2010 2
2011 1
2012 3
2013 2
2014 2
2015 2
2016 4
2017 4
2018 6
2019 1
2020 8
2021 6
2022 4
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Collins DM, Madden SF, Gaynor N, AlSultan D, Le Gal M, Eustace AJ, Gately KA, Hughes C, Davies AM, Mahgoub T, Ballot J, Toomey S, O'Connor DP, Gallagher WM, Holmes FA, Espina V, Liotta L, Hennessy BT, O'Byrne KJ, Hasmann M, Bossenmaier B, O'Donovan N, Crown J. Collins DM, et al. Among authors: toomey s. Clin Cancer Res. 2021 Feb 1;27(3):807-818. doi: 10.1158/1078-0432.CCR-20-2007. Epub 2020 Oct 29. Clin Cancer Res. 2021. PMID: 33122343 Free PMC article. Clinical Trial.
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
Gaynor N, Blanco A, Madden SF, Moran B, Fletcher JM, Kaukonen D, Ramírez JS, Eustace AJ, McDermott MSJ, Canonici A, Toomey S, Teiserskiene A, Hennessy BT, O'Donovan N, Crown J, Collins DM. Gaynor N, et al. Among authors: toomey s. Br J Cancer. 2023 Oct;129(6):1022-1031. doi: 10.1038/s41416-023-02375-y. Epub 2023 Jul 28. Br J Cancer. 2023. PMID: 37507543 Free PMC article. Clinical Trial.
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).
Richards CE, Elamin YY, Carr A, Gately K, Rafee S, Cremona M, Hanrahan E, Smyth R, Ryan D, Morgan RK, Kennedy S, Hudson L, Fay J, O'Byrne K, Hennessy BT, Toomey S. Richards CE, et al. Among authors: toomey s. Int J Mol Sci. 2023 Jun 23;24(13):10545. doi: 10.3390/ijms241310545. Int J Mol Sci. 2023. PMID: 37445722 Free PMC article.
KMT2C and KMT2D aberrations in breast cancer.
Tinsley E, Bredin P, Toomey S, Hennessy BT, Furney SJ. Tinsley E, et al. Among authors: toomey s. Trends Cancer. 2024 Mar 6:S2405-8033(24)00029-3. doi: 10.1016/j.trecan.2024.02.003. Online ahead of print. Trends Cancer. 2024. PMID: 38453563 Review.
COVID-19 contamination of high-touch surfaces in the public domain.
Hennessy NT, Toomey S, Gautier V, O'Reilly S, de Barra E, Hanrahan EO, Hennessy BT. Hennessy NT, et al. Among authors: toomey s. Ir J Med Sci. 2022 Dec;191(6):2839-2840. doi: 10.1007/s11845-021-02881-z. Epub 2022 Jan 10. Ir J Med Sci. 2022. PMID: 35001334 Free PMC article. No abstract available.
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
Dowling GP, Toomey S, Bredin P, Parker I, Mulroe E, Marron J, McLoughlin O, Teiserskiene A, Power C, O'Shea AM, Greally M, Morris PG, Duke D, Hill ADK, Hennessy BT. Dowling GP, et al. Among authors: toomey s. BMC Cancer. 2024 Jan 17;24(1):91. doi: 10.1186/s12885-024-11851-4. BMC Cancer. 2024. PMID: 38233810 Free PMC article.
53 results